7*24 Hotline：
Lizhu Pharmaceutical Group Co., Ltd. (000513)
Founded in January 1985, Lizhu Pharmaceutical Group Co., Ltd. has a registered capital of 935million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical R & D, production and sales, with more than 8000 employees. In 1993, Lizhu A and B shares were listed successively; in 2014, the company completed the conversion of B shares to H shares, which is a few pharmaceutical listed companies with a + H shares in the capital market.
In 2020, the company's operating income was 10.52 billion yuan, net profit was 2.131 billion yuan, and R & D investment was 989 million yuan.
The company has made breakthroughs in the fields of chemical, biological, biochemical, in vitro diagnostic reagents, APIs, traditional Chinese medicine, etc., and the products are distributed in digestion, cardio cerebrovascular, reproductive endocrine, spirit / nerve, anti infection, anti-tumor and other fields.
Chemical field: after lizudele, from the national 1.1 new drug iprazole enteric solution tablets to the injection of eprazole sodium, it took more than ten years to develop another heavy-weight star series products in the field of digestion.
Sphere of microspheres: Lizhu is one of the first companies in China to have the microspheres products listed. There are several exploratory new drug research and development projects in progress, and are the only enterprises in China to declare 3-month sustained release microspheres.
Bio medicine field: it has built a typical demonstration base for the industrialization of antibody drugs in Guangdong Province, and has integrated the technology platform from human antibody, cell line screening, large-scale cell culture, purification, preparation, analysis and detection and quality control.
Diagnostic reagent field: it has several technical platforms such as enzyme immunity, colloidal gold, microorganism, molecular detection, multiple immunity, etc., and has a leading market share in the fields of respiratory tract infection, infectious diseases, drug concentration monitoring and so on.
API field: multiple products have the first global / national market share, and established long-term strategic partnership with well-known enterprises such as Pfizer, Teva, PERT and shuotan, and has been rated as the quality supplier of international market.
oil wellhead